









市场行情
/
股票
/
nasdaq-crmd
/

CorMedix Inc

CRMD

7.145USD

+0.055+0.78%

交易中（美东）报价延迟15分钟

559.80M总市值

3.01市盈率 TTM



CorMedix Inc

7.145

+0.055+0.78%

概览公司财务分析

概览

公司

财务

分析

关于 CorMedix Inc 公司

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

CorMedix Inc简介



公司代码CRMD

公司名称CorMedix Inc

上市日期Mar 25, 2010

CEOTodisco (Joseph)

员工数量64

证券类型Ordinary Share

年结日Mar 25

公司地址300 Connell Drive

城市BERKELEY HEIGHTS

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编07922

电话19085179500

网址https://cormedix.com/

公司代码CRMD

上市日期Mar 25, 2010

CEOTodisco (Joseph)

CorMedix Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Joseph (Joe) Todisco

Chief Executive Officer, Director

302.20K

Mr. Steven W. Lefkowitz

Independent Director

87.65K

-40000.00%

Ms. Susan Blum

Chief Financial Officer

69.69K

+69686.00%

Ms. Janet M. Dillione

Independent Director

23.47K

Mr. Gregory Scott (Greg) Duncan

Independent Director

13.33K

+13333.00%

Mr. Robert Stewart

Independent Director

11.00K

Mr. Myron M. Kaplan, J.D.

Independent Chairman of the Board

Dr. Alan William Dunton, M.D.

Independent Director

Ms. Elizabeth (Liz) Massonhurlburt

Chief Operating Officer

Dr. Matthew T. (Matt) David, M.D.

Chief Business Officer

名称

名称/职务

职务

持股

持股变动

Mr. Joseph (Joe) Todisco

Chief Executive Officer, Director

302.20K

Mr. Steven W. Lefkowitz

Independent Director

87.65K

-40000.00%

Ms. Susan Blum

Chief Financial Officer

69.69K

+69686.00%

Ms. Janet M. Dillione

Independent Director

23.47K

Mr. Gregory Scott (Greg) Duncan

Independent Director

13.33K

+13333.00%

Mr. Robert Stewart

Independent Director

11.00K

收入明细

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

104.28M

0.00%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

6.40%

Deep Track Capital LP

6.29%

Abdalkader (Shaibatalhamd Aymen)

5.84%

The Vanguard Group, Inc.

5.03%

Marshall Wace LLP

4.41%

其他

72.03%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

6.40%

Deep Track Capital LP

6.29%

Abdalkader (Shaibatalhamd Aymen)

5.84%

The Vanguard Group, Inc.

5.03%

Marshall Wace LLP

4.41%

其他

72.03%

股东类型

持股股东

占比

Investment Advisor

26.64%

Hedge Fund

16.79%

Investment Advisor/Hedge Fund

15.24%

Individual Investor

6.94%

Research Firm

2.04%

Pension Fund

1.09%

Bank and Trust

0.33%

Insurance Company

0.03%

Venture Capital

0.03%

其他

30.87%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

345

48.63M

61.72%

+3.95M

2025Q3

340

43.85M

56.33%

+8.67M

2025Q2

304

34.76M

43.08%

+9.67M

2025Q1

267

24.95M

43.35%

-4.41M

2024Q4

241

23.99M

39.87%

+4.76M

2024Q3

216

19.17M

36.31%

+1.94M

2024Q2

207

17.23M

38.40%

-272.84K

2024Q1

207

17.37M

41.54%

-5.46M

2023Q4

207

18.82M

39.64%

+838.41K

2023Q3

199

17.96M

39.30%

-1.31M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

5.04M

6.4%

+248.22K

+5.18%

Sep 30, 2025

Deep Track Capital LP

4.96M

6.29%

+4.46M

+891.10%

Nov 21, 2025

Abdalkader (Shaibatalhamd Aymen)

4.65M

6.22%

+4.65M

Aug 08, 2025

The Vanguard Group, Inc.

3.96M

5.03%

-347.89K

-8.07%

Sep 30, 2025

Marshall Wace LLP

3.47M

4.41%

+893.52K

+34.63%

Sep 30, 2025

Deerfield Management Company, L.P.

3.32M

4.22%

+3.32M

Sep 30, 2025

State Street Investment Management (US)

1.84M

2.33%

+233.97K

+14.61%

Sep 30, 2025

Geode Capital Management, L.L.C.

1.81M

2.3%

+213.45K

+13.37%

Sep 30, 2025

Citadel Advisors LLC

1.72M

2.18%

+2.87K

+0.17%

Sep 30, 2025

Alyeska Investment Group, L.P.

1.26M

1.6%

+512.98K

+68.40%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

State Street SPDR S&P Pharmaceuticals ETF

2.01%

Invesco Biotechnology & Genome ETF

1.87%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.52%

VictoryShares Small Cap Free Cash Flow ETF

0.79%

First Trust Active Factor Small Cap ETF

0.3%

Janus Henderson Small Cap Growth Alpha ETF

0.25%

ALPS Barron's 400 ETF

0.21%

Janus Henderson Small/Mid Cap Growth Alpha ETF

0.19%

Vanguard US Multifactor ETF

0.16%

iShares Micro-Cap ETF

0.15%

State Street SPDR S&P Pharmaceuticals ETF

占比2.01%

Invesco Biotechnology & Genome ETF

占比1.87%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.52%

VictoryShares Small Cap Free Cash Flow ETF

占比0.79%

First Trust Active Factor Small Cap ETF

占比0.3%

Janus Henderson Small Cap Growth Alpha ETF

占比0.25%

ALPS Barron's 400 ETF

占比0.21%

Janus Henderson Small/Mid Cap Growth Alpha ETF

占比0.19%

Vanguard US Multifactor ETF

占比0.16%

iShares Micro-Cap ETF

占比0.15%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据

常见问题

CorMedix Inc的前五大股东是谁？



CorMedix Inc 的前五大股东如下：
BlackRock Institutional Trust Company, N.A.持有股份：5.04M，占总股份比例：6.40%。
Deep Track Capital LP持有股份：4.96M，占总股份比例：6.29%。
Abdalkader (Shaibatalhamd Aymen)持有股份：4.65M，占总股份比例：6.22%。
The Vanguard Group, Inc.持有股份：3.96M，占总股份比例：5.03%。
Marshall Wace LLP持有股份：3.47M，占总股份比例：4.41%。